Antibody Information

General Information of This Antibody
Antibody ID
ANI0UWTSU
Antibody Name
Atezolizumab
Brand Name
TECENTRIQ
Organization
Genentech, Inc.; Roche Holding AG
Indication
Non-small cell lung cancer; Breast cancer; Renal cancer; Melanoma; Bladder cancer; Renal cell carcinoma; Triple-negative breast cancer; Urothelial carcinoma
Approval Date
May. 2016
Synonyms
MPDL3280A; RG7446; 0INE2SFD9E; MPDL-3280A; RG7446; RG-7446; TECENTRIQ
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Programmed cell death 1 ligand 1 (CD274)
  Antigen Info 
ChEMBI ID
CHEMBL3707227
PDB ID
5xxy , 5x8l
DrugBank ID
DB11595
Drug Central ID
5151
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYAST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
GNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Varible Domain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS
    Click to Show/Hide
Heavy Chain Constant Domain 1
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
    Click to Show/Hide
Heavy Chain Constant Domain 2
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
    Click to Show/Hide
Heavy Chain Constant Domain 3
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Hinge Region
EPKSCDKTHTCPPCP
    Click to Show/Hide
Heavy Chain CDR 1
GFTFSDSW
    Click to Show/Hide
Heavy Chain CDR 2
ISPYGGST
    Click to Show/Hide
Heavy Chain CDR 3
ARRHWPGGFDY
    Click to Show/Hide
Light Chain Sequence
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK
    Click to Show/Hide
Light Chain Constant Domain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain CDR 1
QDVSTA
    Click to Show/Hide
Light Chain CDR 2
SAS
    Click to Show/Hide
Light Chain CDR 3
QQYLYHPAT
    Click to Show/Hide
The Activity Data of This Antibody
Antibody Activity Information 1 [1]
Half Maximal Effective Concentration (EC50)
0.9
nM
Antibody Function Confirm the effect of the drug conjugation with the anti PD-L1 mAb and ADC on binding activity to cell line.
Antibody Antigen Binding Assay Enzyme-linked immunosorbent assay (ELISA) was performed on ADC 3 to assess their affinities for the PD-L1 protein.
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
PDL1-Dox ADC [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.25 uM
Positive PDL1 expression (PDL1+++/++)
Method Description
The MTT-based cytotoxicity assay in MDA-MB-231 cells that displayed a dose dependent cell killing of PDL1-Dox treatment.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
PD-L1 ADC 3 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
9.75 nM
High PD-L1 expression (PD-L1+++)
Method Description
The in vitro cytotoxicity of ADC 3 was quickly evaluated in three PD-L1-positive cell lines, ie, MDA-MB-231, PC 9, and A431, and one PD-L1-negative cell line, ie, Romas.
In Vitro Model Lung adenocarcinoma PC-9 cells CVCL_B260
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
10.33 nM
High PD-L1 expression (PD-L1+++)
Method Description
The in vitro cytotoxicity of ADC 3 was quickly evaluated in three PD-L1-positive cell lines, ie, MDA-MB-231, PC 9, and A431, and one PD-L1-negative cell line, ie, Romas.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
11.94 nM
High PD-L1 expression (PD-L1+++)
Method Description
The in vitro cytotoxicity of ADC 3 was quickly evaluated in three PD-L1-positive cell lines, ie, MDA-MB-231, PC 9, and A431, and one PD-L1-negative cell line, ie, Romas.
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
References
Ref 1 Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorg Chem. 2021 Nov;116:105366.
Ref 2 PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer. Cancers (Basel). 2019 Feb 16;11(2):232. doi: 10.3390/cancers11020232.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.